Human Nutrition
Lallemand Human Nutrition specializes in supplying mineral- and vitamin-rich yeast and probiotic bacteria for human health
In the early 20th century, Lallemand focused on the production of yeast for the North American baking industry. Using the acquired knowledge and the technological assets in microbiology and fermentation as a base, it has come to serve the needs of other industries through the production of specialty yeast, bacteria and derivatives.
Today, Lallemand is a world leader in supplying yeast and bacteria to various industries, including human health and nutrition.
Production
Lallemand Human Nutrition specializes in supplying mineral- and vitamin-rich yeast and probiotic bacteria, as well as cranberry, cocoa, herbal and other antioxidant-rich ingredients, in addition to proprietary strains of bacteria and yeast formulations for various digestive and immunity health conditions, plus bacterial lysate used to improve patients’ general or specific immunity.
Quality assurance
To ensure all our yeast and bacteria products meet the highest standards of quality, strict controls are applied at every stage of the production process – from the Petri dish to large-scale fermentation, lyophilization, microencapsulation and formulation.
Lallemand ongoing investments in optimizing production conditions have earned the two principal bacteria-manufacturing sites in France and Canada the prestigious Good Manufacturing Practices (GMP) certification from Health Canada and from the International Conference on Harmonisation for Active Pharmaceutical Ingredients (ICHQ7A), the GMP Pharma certification for Active Pharmaceutical Ingredients, and the Drug Product Pharma for finished products from the AFSSA.
Research and development
From the beginning, Lallemand Human Nutrition has been committed to continuous innovation. Our main areas of research focus on fermentation and strain improvement processes, and on factors influencing the technological performance of our strains.
The acquisition of Institut Rosell in 1998 paved the way to exciting new possibilities in the area of research henceforth focused on the scientific and clinical documentation of probiotic formulations designed specifically for their health benefits.
Dedicated to continuously improving scientific performance, throughout the years Lallemand has forged numerous alliances and collaborative relationships with international public and private partners, which include universities, hospitals, pharmaceutical companies and world-renowned research centres located primarily in North America and Europe (including McGill University, Université de Montréal, University of Saskatchewan, the Agriculture and Agri-Food Canada Food Research and Development Centre in Saint-Hyacinthe, the National Research Council Biotechnology Research Institute, INRA Toulouse, Rome University, University of New South Wales, the Assistance publique – Hôpitaux de Paris [AP-HP] with the CHU [university hospital] Louis-Mourier in Colombes, CHU Nice and the CHU Rouen, the University of Milan Department of Public Health – Microbiology – Virology, Biofortis Nantes, and the Hospital for Sick Children affiliated with the University of Toronto, among others).
The fundamental purpose of these affiliations is to bring the best expertise to Lallemand’s strains and finished products in the areas of strain grading, pharmacological and analysis of the mode of action toxicological assessment, as well as pre-clinical and clinical trials performed on our probiotic yeast and bacteria and on our mineral-enriched yeasts.
